In a warning letter to the company's CEO and MD Nimish Chudgar, the US Food and Drug Administration (USFDA) has pointed out various manufacturing lapses at the Matoda-Sanand, Ahmedabad-based facility.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cmG35ga
via IFTTT
No comments:
Post a Comment